Literature DB >> 19390431

Lupus nephritis.

Sandeep Singh1, Ramesh Saxena.   

Abstract

Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus. Kidney biopsy remains a mainstay of LN diagnosis, which is usually prompted by abnormal urinary sediment, proteinuria, or elevated creatinine. New International Society of Nephrology/Renal Pathology Society classification of LN tends to remove some of the ambiguities of World Health Organization classification and results in better categorization of patients. Although prognosis of LN has improved with the combined use of cytotoxic and steroid therapy, up to 20% of these patients progress to renal failure. Moreover, toxicity of the current regimens remains a major concern. Last few decades have seen a tremendous progress being made in understanding the pathogenesis of LN, but a little has been added to armamentarium against LN, leaving physicians with a few choices. Fortunately, with unfolding of molecular processes involved in disease pathogenesis, new targets for drug therapy have emerged. Whether these medications will prove to be more efficacious and less toxic remains a matter of debate and will be answered by several ongoing trials and future studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390431     DOI: 10.1097/MAJ.0b013e3181907b3d

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

1.  Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice.

Authors:  Xi-Li Wu; Wang-Gang Zhang; Xing-Min Shi; Peng An; Wan-Sen Sun; Cheng-Lin Qiao; Zhu Wang
Journal:  Chin J Integr Med       Date:  2011-04-21       Impact factor: 1.978

Review 2.  Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.

Authors:  Abhigyan Satyam; Ryo Hisada; Rhea Bhargava; Maria G Tsokos; George C Tsokos
Journal:  Transl Res       Date:  2022-03-14       Impact factor: 10.171

3.  Fli-1 transcription factor affects glomerulonephritis development by regulating expression of monocyte chemoattractant protein-1 in endothelial cells in the kidney.

Authors:  Eiji Suzuki; Eva Karam; Sarah Williams; Dennis K Watson; Gary Gilkeson; Xian K Zhang
Journal:  Clin Immunol       Date:  2012-09-28       Impact factor: 3.969

4.  Fli-1 controls transcription from the MCP-1 gene promoter, which may provide a novel mechanism for chemokine and cytokine activation.

Authors:  Mara L Lennard Richard; Tamara K Nowling; Danielle Brandon; Dennis K Watson; Xian K Zhang
Journal:  Mol Immunol       Date:  2014-08-06       Impact factor: 4.407

Review 5.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

6.  Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis.

Authors:  Sandeep Singh; Tianfu Wu; Chun Xie; Kamala Vanarsa; Jie Han; Tina Mahajan; Ho Bing Oei; Chul Ahn; Xin J Zhou; Chaim Putterman; Ramesh Saxena; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2012-07-13       Impact factor: 5.156

7.  Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Authors:  Ellen M Ginzler; Stephen Wax; Anand Rajeswaran; Samuel Copt; Jan Hillson; Eleanor Ramos; Nora G Singer
Journal:  Arthritis Res Ther       Date:  2012-02-07       Impact factor: 5.156

8.  IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment.

Authors:  Agneta Zickert; Petra Amoudruz; Yvonne Sundström; Johan Rönnelid; Vivianne Malmström; Iva Gunnarsson
Journal:  BMC Immunol       Date:  2015-02-12       Impact factor: 3.615

9.  A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis.

Authors:  Carolina Landolt-Marticorena; Stephenie D Prokopec; Stacey Morrison; Babak Noamani; Dennisse Bonilla; Heather Reich; James Scholey; Carmen Avila-Casado; Paul R Fortin; Paul C Boutros; Joan Wither
Journal:  Arthritis Res Ther       Date:  2016-10-04       Impact factor: 5.156

10.  Interferon (IFN)-λ is a potential mediator in lupus nephritis.

Authors:  Agneta Zickert; Vilija Oke; Ioannis Parodis; Elisabet Svenungsson; Yvonne Sundström; Iva Gunnarsson
Journal:  Lupus Sci Med       Date:  2016-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.